Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CORE OZK X CC (also known as CORE OZK X CC 24:01) is an Indica-dominant hybrid medical cannabis flower developed and produced in Germany by DEMECAN. It is derived from a genetic cross of OZ Kush and Coffin Candy (or Runtz x (Z x (Gelato 33 x 18 Coffins))). The product contains approximately 24% tetrahydrocannabinol (THC) and less than 1% cannabidiol (CBD). It is prescribed as an unbestrahlte (unirradiated) medical cannabis flower for inhalation or vaporization to treat conditions such as sleep disorders, anxiety, stress, and chronic pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CORE OZK X CC.